Upping the ante on antibodies

被引：77
作者：
Baker, M
机构：
来源：
NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 09期
关键词：
D O I：
10.1038/nbt0905-1065
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The current generation of antibodies has done more than make a few companies rich. It has laid the groundwork for ambitious companies to move to maturity. © 2005 Nature Publishing Group.
引用
收藏
页码：1065 / 1072
页数：8
相关论文
共 4 条
[1]  
EVANS D, 2005, MONOCLONAL ANTIBODIE
[2]   Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody [J].
Lu, D ;
Zhang, HF ;
Ludwig, D ;
Persaud, A ;
Jimenez, X ;
Burtrum, D ;
Balderes, P ;
Liu, ML ;
Bohlen, P ;
Witte, L ;
Zhu, ZP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (04) :2856-2865
[3]   Next-generation monoclonals less profitable than trailblazers? [J].
Mitchell, P .
NATURE BIOTECHNOLOGY, 2005, 23 (08) :906-906
[4]   Antibody engineering for therapeutics [J].
Presta, L .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2003, 13 (04) :519-525
1